Swiss (SMI) Life Sciences Industry Analysis

UpdatedJun 04, 2026

DataAggregated Company Financials

Companies7

7D-3.3%
3M-0.8%
1Y-8.7%
YTD-3.5%

Over the last 7 days, the Life Sciences industry has dropped 3.3%, driven by pullbacks in Bachem Holding and Lonza Group of 14% and 2.2%, respectively. In contrast, Tecan Group has gained 6.7%. However, the industry is down 8.7% over the past year. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 05 Jun 2026	CHF 47.1b	CHF 10.1b	CHF 1.1b	35.9x	43.2x	4.7x
Sun, 03 May 2026	CHF 46.1b	CHF 10.1b	CHF 1.1b	35.7x	40.3x	4.6x
Tue, 31 Mar 2026	CHF 46.5b	CHF 10.1b	CHF 1.1b	32x	40.7x	4.6x
Thu, 26 Feb 2026	CHF 48.8b	CHF 10.1b	CHF 1.3b	29.7x	37.8x	4.8x
Sat, 24 Jan 2026	CHF 52.3b	CHF 10.6b	CHF 1.1b	33.5x	47.6x	4.9x
Mon, 22 Dec 2025	CHF 48.6b	CHF 10.6b	CHF 1.1b	28.7x	44.2x	4.6x
Wed, 19 Nov 2025	CHF 47.4b	CHF 10.6b	CHF 1.1b	27x	43.1x	4.5x
Fri, 17 Oct 2025	CHF 50.1b	CHF 10.6b	CHF 1.1b	30.2x	45.6x	4.7x
Sun, 14 Sep 2025	CHF 51.0b	CHF 10.6b	CHF 1.1b	32.8x	46.3x	4.8x
Tue, 12 Aug 2025	CHF 51.4b	CHF 10.7b	CHF 1.1b	33.3x	44.7x	4.8x
Thu, 10 Jul 2025	CHF 52.3b	CHF 10.1b	CHF 1.0b	32.8x	50.4x	5.2x
Sat, 07 Jun 2025	CHF 53.4b	CHF 10.1b	CHF 1.0b	32.2x	51.4x	5.3x
Mon, 05 May 2025	CHF 55.0b	CHF 10.1b	CHF 1.0b	31.5x	52.9x	5.5x
Wed, 02 Apr 2025	CHF 51.3b	CHF 10.1b	CHF 1.0b	31.5x	50x	5.1x
Fri, 28 Feb 2025	CHF 54.6b	CHF 10.1b	CHF 1.0b	30.6x	52.3x	5.4x
Sun, 26 Jan 2025	CHF 57.2b	CHF 10.2b	CHF 943.1m	36.3x	60.6x	5.6x
Tue, 24 Dec 2024	CHF 52.4b	CHF 10.2b	CHF 943.5m	35.4x	55.5x	5.1x
Thu, 21 Nov 2024	CHF 52.4b	CHF 10.2b	CHF 943.6m	40.7x	55.6x	5.1x
Sat, 19 Oct 2024	CHF 56.1b	CHF 10.2b	CHF 943.4m	42.3x	59.5x	5.5x
Mon, 16 Sep 2024	CHF 57.5b	CHF 10.2b	CHF 937.0m	44.5x	61.3x	5.6x
Wed, 14 Aug 2024	CHF 56.4b	CHF 10.2b	CHF 923.6m	45.1x	61.1x	5.5x
Fri, 12 Jul 2024	CHF 55.5b	CHF 10.3b	CHF 1.0b	47.8x	55.4x	5.4x
Sun, 09 Jun 2024	CHF 53.1b	CHF 10.3b	CHF 1.0b	44x	53x	5.2x
Tue, 07 May 2024	CHF 54.3b	CHF 10.3b	CHF 1.0b	43.5x	54.2x	5.3x
Thu, 04 Apr 2024	CHF 58.2b	CHF 10.3b	CHF 1.0b	45.8x	58.1x	5.7x
Sat, 02 Mar 2024	CHF 50.7b	CHF 10.2b	CHF 982.2m	47x	51.7x	5x
Mon, 29 Jan 2024	CHF 46.5b	CHF 10.2b	CHF 1.0b	42.3x	45.6x	4.6x
Wed, 27 Dec 2023	CHF 41.8b	CHF 9.8b	CHF 1.5b	32.4x	28x	4.3x
Fri, 24 Nov 2023	CHF 41.4b	CHF 9.8b	CHF 1.5b	29.9x	27.7x	4.2x
Sun, 22 Oct 2023	CHF 38.3b	CHF 9.8b	CHF 1.5b	26.9x	25.7x	3.9x
Tue, 19 Sep 2023	CHF 46.8b	CHF 9.8b	CHF 1.5b	32.7x	31.4x	4.8x
Thu, 17 Aug 2023	CHF 52.0b	CHF 9.7b	CHF 1.5b	40.4x	33.9x	5.3x
Sat, 15 Jul 2023	CHF 56.4b	CHF 9.7b	CHF 1.6b	36.1x	34.5x	5.8x
Mon, 12 Jun 2023	CHF 58.7b	CHF 9.7b	CHF 1.6b	37x	35.9x	6.1x

Price to Earnings Ratio

35.9x

Mon, 12 Jun 2023

Current Industry PE

Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 43.2x which is lower than its 3-year average PE of 46.3x.

The industry is trading close to its 3-year average PS ratio of 5.0x.

Past Earnings Growth

The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
Meanwhile revenues have remained mostly flat.
This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.